Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection. (December 2017)

• Record Type: Journal Article
• Authors: Liu, Haiyan; Triboulet, Melanie; Zia, Amin; Vuppalapaty, Meghah; Kidess-Sigal, Evelyn; Coller, John; Natu, Vanita; Shokoohi, Vida; Che, James; Renier, Corinne; Chan, Natalie; Hanft, Violet; Jeffrey, Stefanie; Sollier-Christen, Elodie
• Is Part Of: Npj genomic medicine. Volume 2(2017)
• Page Start: 1
• Page End: 13
• Publication Date: 2017-12
• Subjects: Medical genetics -- Periodicals; Genomics -- Periodicals; 611.01816
• DOI: 10.1038/s41525-017-0034-3
• Languages: English
• ISSNs: 2056-7944

Abstract

Abstract Genomic characterization of circulating tumor cells (CTCs) may prove useful as a surrogate for conventional tissue biopsies. This is particularly important as studies have shown different mutational profiles between CTCs and ctDNA in some tumor subtypes. However, isolating rare CTCs from whole blood has significant hurdles. Very limited DNA quantities often can't meet NGS requirements without whole genome amplification (WGA). Moreover, white blood cells (WBC) germline contamination may confound CTC somatic mutation analyses. Thus, a good CTC enrichment platform with an efficient WGA and NGS workflow are needed. Here, Vortex label-free CTC enrichment platform was used to capture CTCs. DNA extraction was optimized, WGA evaluated and targeted NGS tested. We used metastatic colorectal cancer (CRC) as the clinical target, HCT116 as the corresponding cell line, GenomePlex® and REPLI-g as the WGA methods, GeneRead DNAseq Human CRC Panel as the 38 gene panel. The workflow was further validated on metastatic CRC patient samples, assaying both tumor and CTCs. WBCs from the same patients were included to eliminate germline contaminations. The described workflow performed well on samples with sufficient DNA, but showed bias for rare cells with limited DNA input. REPLI-g provided an unbiased amplification on fresh rare cells, enabling an accurate variant calling using the targeted NGS. Somatic variants were detected in patient CTCs and not found in age matched healthy donors. This demonstrates the feasibility of a simple workflow for clinically relevant monitoring of tumor genetics in real time and over the course of a patient's therapy using CTCs. Liquid biopsy: Simple workflow allows DNA analysis of circulating tumor cells A microfluidic device that isolates cancer cells circulating in a blood sample allows for real-time genetic monitoring. A team led by Elodie Sollier-Christen of Vortex Biosciences, a cancer diagnostics company in Menlo Park, California, USA, in collaboration with Professor Stefanie Jeffrey at Stanford University School of Medicine, developed a simple workflow for analyzing the genomes of rare circulating tumor cells (CTCs) found in the bloodstream after they've been collected through a proprietary microfluidic system. They optimized rare cell DNA extraction, compared different whole genome amplification methods, and then tested the workflow on blood samples from patients with metastatic colorectal cancer. The analysis also included white blood cells from the same patients to parse cancer-causing mutations from inherited ones. The method could aid in the translation of liquid biopsies for the clinical care of cancer patients.